Compare KKR & Co Inc (KKR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? KKR & Co Inc trades at $85.5 (market cap $78.24B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: KKR & Co Inc is far larger — about 80.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and KKR & Co Inc pays a 0.89% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| KKR | MRVI | |
|---|---|---|
Market Cap | $78.24B | $972.90M |
Volume | 9,217,096 | 4,325,710 |
Sector | Financials | Health |
52-Week High | $142.75 | $9.00 |
52-Week Low | $83.88 | $2.83 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $795.68M | $1.08B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR's stock is trading at $85.60, down 6.46% in the last session amid a bearish technical outlook. The company maintains strong profitability with a 14.97% net income margin and has beaten earnings estimates in two of the last three quarters. Recent business developments include multiple strategic investments and joint ventures, including a partnership with Thomson Reuters and new equipment finance platform Akrapoint Commercial Capital.
Despite near-term price weakness, KKR presents a compelling investment case with strong analyst support (88.9% buy ratings) and a consensus price target of $123.20 representing 44% upside. Key risks include volatile cash flow patterns and high leverage, but the company's diversified investment platform and active deal pipeline support long-term growth prospects.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
